| Date | Company | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 14 Jun 24 | LYEL Lyell Immunopharma | Option Common Stock | Grant | Acquire A | No | No | 2.36 | 130,000 | 306.80 k | 130,000 |
| 12 Jun 24 | PRME Prime Medicine | Stock Option Common Stock | Grant | Acquire A | No | No | 7.68 | 45,000 | 345.60 k | 45,000 |
| 10 Jun 24 | RAPP Rapport Therapeutics, Inc. Common Stock | Common Stock | Conversion | Acquire C | Yes | No | 0 | 3,728,738 | 0.00 | 3,728,738 |
| 10 Jun 24 | RAPP Rapport Therapeutics, Inc. Common Stock | Series B Preferred Stock Common Stock | Conversion | Dispose C | Yes | No | 0 | 11,924,138 | 0.00 | 0 |
| 10 Jun 24 | RAPP Rapport Therapeutics, Inc. Common Stock | Series A Preferred Stock Common Stock | Conversion | Dispose C | Yes | No | 0 | 20,000,000 | 0.00 | 0 |
| 6 Jun 24 | SANA Sana Biotechnology | Stock Option Common Stock | Grant | Acquire A | No | No | 7.36 | 54,278 | 399.49 k | 54,278 |
